Pharma Commercialisation Services

CG Results Healthcare has a long and distinguished history supporting transactions for companies that service the commercialisation of pharmaceuticals and devices by pharma, generic and medical device companies.

CG Results executed its first transaction in this sector in 1998 with the sale of Adelphi to Omnicom Group. More recently we’ve worked on the sale of iSafety Systems, an Indian pharmacovigilance company which we sold to ProPharma Group, a US company providing drug regulatory services to pharma, generic and biotech companies, in 2021. Between these dates CG Results Healthcare has been involved in many transactions with a wide range of companies (founder owned or PE-backed) that provide expert services including digital transformation, consulting, analytics, market access, salesforce training, PR and media, to the healthcare industry.

Pharma Commercialisation Services Deals

Nov 2021
has received investment from
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Jun 2021
has been acquired by
Apr 2021
has invested in
Mar 2021
has invested in
Jun 2020
has been acquired by
Jun 2020
has been acquired by
Oct 2019
has acquired
Oct 2019
US division
US division, has been acquired by

Latest Insights

Reports
16th February 2023

Pharma Commercialisation Services Update – February 2023

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. In this report we will be reviewing deal activity across 2022 and taking a look forward to see what 2023 may hold for the sector. We hope that you enjoy this report and look forward to discussing the data and underlying themes with […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Reports
27th September 2022

Pharma Commercialisation Services Update – September 2022

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]